Article Sidebar

PDF (Tiếng Việt)
Published: 2025-05-20
Abstract Views: 36
Views PDF (Tiếng Việt): 19
DOI: https://doi.org/10.52163/yhc.v66iCD8.2571
Issue
Vol. 66 No. CĐ8-NCKH
Section
Articles
How to Cite
Hạnh, N. Đức, & An, N. T. B. (2025). 25. INPATIENT TREATMENT COSTS OF PATIENTS WITH DRUG-RESISTANT TUBERCULOSIS AT THE NATIONAL LUNG HOSPITAL IN 2024. Vietnam Journal of Community Medicine, 66(CĐ8-NCKH). https://doi.org/10.52163/yhc.v66iCD8.2571

25. INPATIENT TREATMENT COSTS OF PATIENTS WITH DRUG-RESISTANT TUBERCULOSIS AT THE NATIONAL LUNG HOSPITAL IN 2024

Nguyen Duc Hanh1, Nguyen Thi Binh An2
1 National Lung Hospital
2 Thang Long University

Main Article Content

Abstract

Objective: This study aims to describe the inpatient treatment costs and cost structure of patients with drug-resistant tuberculosis at the National Lung Hospital in 2024.


Subjects and methods: A cross-sectional descriptive study using retrospective data from medical records and hospital invoices of patients treated in 2024. The total number of inpatients with drug-resistant tuberculosis during the year was 629 patients.


Results: The average total treatment cost per patient was VND 35,170,000. The highest cost were non-tuberculosis medications (38%), then laboratory tests (21.6%), and hospital bed-days (17.3%). Health insurance covered 61.6% of the total cost, while medical out -of- pocket cost accounted for 38.4%.


Conclusion: The treatment cost of drug-resistant tuberculosis is considerably high, particularly due to the expenses for non-tuberculosis medications, laboratory testing, and hospital stays.

Article Details

Keywords

Treatment cost, drug-resistant tuberculosis.

References

[1] WHO. Global tuberculosis report 2023. Geneva: World Health Organization, 2023.
[2] Farhat M, Cox H, Ghanem M et al. Drug-resistant tuberculosis: a persistent global health concern. Current Opinion in Pulmonary Medicine, 2024, 22 (10): 617-635.
[3] Akalu T.Y, Clements A.C.A, Wolde H.F et al. Economic burden of multidrug-resistant tuberculosis on patients and households: a global systematic review and meta-analysis. Scientific Reports, 2023, 13 (1): 22361.
[4] Phạm T.A.N, Forse R, Codlin A.J et al. Determinants of catastrophic costs among households affected by MDR-TB in Ho Chi Minh city, Viet Nam: a prospective cohort study. BMC Public Health, 2023, 23 (1): 2372.
[5] Hoàng Đình Tiếng, Phạm Thị Tố Liên, Nguyễn Thị Linh Tuyền và cộng sự. Chi phí y tế trong điều trị bệnh lao phổi nội trú có bảo hiểm y tế: Nghiên cứu cắt ngang tại Bệnh viện Phổi Vĩnh Long năm 2023. Tạp chí Y học Việt Nam, 2024, 538 (2): 104-109.
[6] Diel R, Sotgiu G, Andres S et al. Cost of multidrug resistant tuberculosis in Germany - an update. Int J Infect Dis, 2021, 103: 102-109.
[7] Pooran A, Pieterson E, Davids M et al. What is the cost of diagnosis and management of drug-resistant tuberculosis in South Africa? PLoS ONE, 2013, 8 (1): e54587.
[8] Kaurav Y, Bharti A Catastrophic “costs”: A hindrance to eliminate tuberculosis. Indian J Tuberc, 2023, 70 (2): 147-148.